{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001231","form_type":"8-K","ticker":"BCRX","cik":"0000882796","company_name":"BIOCRYST PHARMACEUTICALS INC","filed_at":"2025-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.656066+00:00","generated_at":"2026-05-25T16:33:25.923571+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioCryst CFO Anthony Doyle to resign effective April 9, 2025; search underway","bullets":["Anthony Doyle notified resignation as CFO effective April 9, 2025.","Resignation is not due to any disagreement with the company.","Company has initiated a search for a new CFO; Doyle will remain to assist transition.","Doyle joined in April 2020, helped launch ORLADEYO and strengthen financial position."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001231","json":"https://secwatch.observer/filing/0001171843-25-001231.json","markdown":"https://secwatch.observer/filing/0001171843-25-001231.md","text":"https://secwatch.observer/filing/0001171843-25-001231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882796/000117184325001231/0001171843-25-001231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882796/000117184325001231/f8k_030425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T16:33:25.923571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"370644ffb8","claim":"Anthony Doyle resigned as Chief Financial Officer at BIOCRYST PHARMACEUTICALS INC.","evidence_excerpt":"On February 28, 2025, Anthony Doyle, the Chief Financial Officer of BioCryst Pharmaceuticals, Inc. (the “Company”) notified the Company of his intention to resign from his employment with the Company, effective April 9, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882796/000117184325001231/0001171843-25-001231-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}